Alice Chen

EVP
​Accelerator Life Science Partners

​​​​
​

Alice Chen, PhD., is an experienced life sciences operating executive and investment professional and serves as the Executive Vice President at ALSP. In her role at ALSP, Alice has been actively involved in sourcing and evaluating emerging biotechnology investment opportunities and has played an instrumental role in the formation, oversight, and transaction of several Accelerator portfolio companies, including Acylin Therapeutics (asset acquisition by a Top 20 global pharmaceutical company), Petra Pharma (acquired by a Top 20 global pharmaceutical company), Nemean Pharma, Rodeo Therapeutics (acquired by Amgen Inc.), Magnolia Neurosciences, and Automera. She currently serves on the Board of Directors for Automera.
Dr. Chen has 20 years of research and drug development experience, principally in small molecule therapeutics. Prior to joining ALSP, Alice served as a scientific consultant and drug development project leader for several venture-backed biotechnology companies. She also served as Director of Technologies at Qwell Pharmaceuticals, a venture-backed biotechnology company developing novel, small-molecule drugs focused on cancer and inflammation. 
Dr. Chen received a Ph.D. in Chemical Engineering from Stanford University and a B.S. degree in Chemical Engineering from U.C. Berkeley. She served as an Engineering Fellow at Merck & Company and is a graduate of the Kauffman Fellows Program (Class 19). Alice served on the board of Life Science Washington, the state’s life-science trade association, for six years prior to her current post as ALSP’s head of operations in Singapore. She is a current member of various technology review committees in the U.S. and abroad.

Speech title & Synopsis

​
Panel Discussion- Innovative Investment Strategies for New Drug Development
 

Panelist